GRC-6211

Add links
Source: Wikipedia, the free encyclopedia.
GRC-6211
Identifiers
  • 1-[(4R)-6-fluorospiro[3,4-dihydrochromene-2,1'-cyclobutane]-4-yl]-3-isoquinolin-5-ylurea
JSmol)
  • C1CC2(C1)C[C@H](C3=C(O2)C=CC(=C3)F)NC(=O)NC4=CC=CC5=C4C=CN=C5
  • InChI=1S/C22H20FN3O2/c23-15-5-6-20-17(11-15)19(12-22(28-20)8-2-9-22)26-21(27)25-18-4-1-3-14-13-24-10-7-16(14)18/h1,3-7,10-11,13,19H,2,8-9,12H2,(H2,25,26,27)/t19-/m1/s1
  • Key:JADKHWDNSKIILG-LJQANCHMSA-N

GRC-6211 is a drug developed by

antiinflammatory effects and reached Phase IIb human trials, but was ultimately discontinued from development as a medicine, though it continues to have applications in scientific research.[1][2][3]

References

  1. PMID 19010489
    .
  2. PMID 19481638
    .
  3. S2CID 7146812
    .
Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=GRC-6211&oldid=1187814643"